Investigational Pipeline

FLAG Therapeutics’ investigational pipeline is comprised of water-soluable, small molecule therapeutics derived from the company’s drug discovery platforms. Each investigational compound exhibits the following characteristics:

  • Multi-acting: Multi-specific targets designed for targeting and killing cancer cells

  • Targeted: Low molecular weight improves target engagement and cell penetration

  • Fights Resistance: Not a substrate for P-glycoprotein (P-gp), a “housekeeping” protein, therefore bypasses efflux pumps

  • De-risked: Well-understood mechanisms of action improve predictability of efficacy and toxicity

FLAG-003, FLAG’s lead investigational product candidate, is projectedto enter Phase 1/2 clinical development shortly.

FLAG is dedicated to developing new treatment options for difficult-to-treat cancers.